A phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of VX-445 combination therapy in subjects with cystic fibrosis who are heterozygous for the F508del mutation and a minimal function mutation (F/MF)
A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting. PROOF-registry new and extended Belgium –Luxembourg
A phase 3, open label, randomised, multi-centre, international study of MEDI4736, versus standard of care in patients with locally advanced or metastatic non-small cell lung cancer (stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen and do not have known EGFR TK activating mutations or ALK rearrangements (ARCTIC)
A double-blind, placebo controlled, multicentre, clinical Trial to investigate the efficacy and safety of 12 months of therapy with inhaled PROMIXIN® (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)”
A randomized, blinded, parallel group, multi-center dose- finding study, to assess the efficacy, safety and tolerability of different doses of Tobramycin inhalation powder in patients with Non-Cystic Fibrosis Bronchiectasis and pulmonary P. aeruginosa infection
A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and intermediate or high probability of group 3 pulmonary hypertension.
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment
A 12-week, double-blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.
A Randomized, double-blind, parallel group, multi-center study to assess the efficacy and safety of PT009 compared to PT005 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD